Kodiak Sciences Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
KOD$108.06+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(123,801) | $(111,774) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 8,221 | 9,197 |
| Stock-based compensation | 23,763 | 31,532 |
| Loss on disposal of long-lived assets | — | 8 |
| Non-cash lease impairment expense | — | 1,910 |
| Amortization of operating lease right-of-use asset | 4,307 | 4,069 |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other current assets | (635) | 108 |
| Other assets | 7 | 68 |
| Accounts payable | 249 | 1,129 |
| Accrued and other current liabilities | 8,066 | 3,636 |
| Operating lease liability | (6,424) | (5,133) |
| Long-term deposit | — | 1,500 |
| Net cash used in operating activities | (86,247) | (63,750) |
| Cash flows from investing activities | ||
| Purchase of property and equipment | (1,294) | (403) |
| Net cash used in investing activities | (1,294) | (403) |
| Cash flows from financing activities | ||
| Payment of public offering costs | (303) | — |
| Proceeds from stock option exercises | 3,779 | 162 |
| Proceeds from issuance of common stock pursuant to ESPP | 106 | 82 |
| Net cash provided by financing activities | 3,582 | 244 |
| Net decrease in cash, cash equivalents and restricted cash | (83,959) | (63,909) |
| Cash, cash equivalents and restricted cash, at beginning of period | 216,046 | 174,258 |
| Cash, cash equivalents and restricted cash, at end of period | $132,087 | $110,349 |
| Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets: | ||
| Cash and cash equivalents | $125,903 | $104,165 |
| Restricted cash | 6,184 | 6,184 |
| Total cash, cash equivalents and restricted cash in consolidated balance sheets | $132,087 | $110,349 |
| Supplemental disclosures of non-cash investing and financing information: | ||
| Purchase of property and equipment under accounts payable and accruals | $855 | $13 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.